Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 617 participants.

Also called NCT04916470

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 617 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04916470
  • EudraCT 2020-004170-22
Other papers using this trial's data
  • Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes The New England journal of medicine, 2024-04-18 DOI, PubMed 38587233
  • Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial The lancet. Diabetes & endocrinology, 2025-03 DOI, PubMed 39848268

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Canada, Czechia, Germany, Hungary, India, Israel, Italy, Japan, Netherlands, Poland, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04916470. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-15 (actual); primary completion 2023-10-11 (actual). Results posted on 2026-11-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
Acronym
STEP HFpEF DM
Condition
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo (Semaglutide)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04916470
Content hash
cc9990d048dd38929da2e29618f42dc14f49c46eb76475abb81ed97713893232